Investigational drug · Phase 3
CBT-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pterygium.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "CBT-001"
First trial start
2022
Jun 30, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CBT-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pterygium
Largest trials
Live from ClinicalTrials.gov: studies naming "CBT-001" as an intervention, largest first.
- A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With PterygiumPivotal-lookingActive, not recruiting
Cloudbreak Therapeutics, LLCIndustry
NCT05456425 · 660 participants · Start Jun 30, 2022 · Primary completion Dec 31, 2026
Drug: CBT-001; Vehicle · For: Pterygium
Sites: Dothan, Alabama; Sun City, Arizona; Bakersfield, California · 44 sites in all
Cloudbreak Therapeutics, LLCIndustry
NCT03049852 · 75 participants · Start Apr 15, 2017 · Primary completion Apr 30, 2018
Drug: CBT-001 single dose; Vehicle and 1 more · For: Pterygium
Sites: Laguna Beach, California
Newest research
PubMed records naming it or its code names, newest first.
- A Phase IIa Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent Pterygium.
Whitcup SM, Sall KN, Hovanesian JA, et al. · Ophthalmol Sci 2024
- Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of CTB-001, a Recently Developed Generic of Bivalirudin.
Han S, Kim YH, Choi HY, et al. · Pharm Res 2019
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.